RIVASTIGMINE TARTRATE | A203148 | MACLEODS PHARMACEUTICALS LTD
Highest NADAC/Unit
$0.1706
per ea
Lowest NADAC/Unit
$0.1584
per ea
Brand NDCs
0
Generic NDCs
8
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 33342009115RIVASTIGMINE 4.5 MG CAPSULE | $0.1706 | EA | Generic | — | 2026-10-21 |
| 33342009109RIVASTIGMINE 4.5 MG CAPSULE | $0.1706 | EA | Generic | — | 2026-10-21 |
| 33342008909RIVASTIGMINE 1.5 MG CAPSULE | $0.1681 | EA | Generic | — | 2026-10-21 |
| 33342008915RIVASTIGMINE 1.5 MG CAPSULE | $0.1681 | EA | Generic | — | 2026-10-21 |
| 33342009015RIVASTIGMINE 3 MG CAPSULE | $0.1626 | EA | Generic | — | 2026-10-21 |
| 33342009009RIVASTIGMINE 3 MG CAPSULE | $0.1626 | EA | Generic | — | 2026-10-21 |
| 33342009209RIVASTIGMINE 6 MG CAPSULE | $0.1584 | EA | Generic | — | 2026-10-21 |
| 33342009215RIVASTIGMINE 6 MG CAPSULE | $0.1584 | EA | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.